Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03929705
Other study ID # AF SA 148
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2, 2019
Est. completion date January 23, 2020

Study information

Verified date July 2020
Source Oxford Immunotec
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.


Description:

The target number of subjects is 100 active TB and 100 active TB excluded . This study will enroll up to 680 subjects (based on previous enrolment rates of approximately 300-350 subjects enrolled for 50 active TB and 50 active TB excluded). Study Duration: 6 months All subjects enrolled in this study will be men or women, aged 18 years or older.


Recruitment information / eligibility

Status Completed
Enrollment 676
Est. completion date January 23, 2020
Est. primary completion date January 23, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Cohort 1a and 1b - • Must be at least 18 years of age - Must be able to provide informed consent - Must be able to provide a minimum of 10 mL of whole blood at each visit (16mL for immunocompromised i.e. HIV+) - Must be T-SPOT.TB positive - First visit suspect TB subjects with no prior history of TB diagnosis Inclusion Criteria: Cohort 2a and 2b - Must be at least 18 years of age - Must be able to provide informed consent - Must be able to provide a minimum of 10 mL of whole blood at each visit (16mL for immunocompromised i.e. HIV+) - Must be T-SPOT.TB positive - No prior history of TB diagnosis Exclusion Criteria: Cohort 1a and 1b - • Negative in the T-SPOT.TB test - Previous or pre-existing confirmed TB diagnosis - On anti-TB treatment for more than 1 week* - Not meeting inclusion criteria Exclusion Criteria: Cohort 2a and 2b - Negative T-SPOT.TB test - Previous or pre-existing confirmed TB diagnosis - On anti-TB treatment - Symptoms of active TB - Not meeting inclusion criteria

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
South Africa University of Cape Town Cape Town

Sponsors (1)

Lead Sponsor Collaborator
Oxford Immunotec

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary T-Spot The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response (NTBSLR) in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA. 6 month study
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06272812 - A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region. Phase 2
Active, not recruiting NCT01875952 - Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Phase 4
Recruiting NCT03808636 - Innovative Reagents for Improving Rapid Diagnosis of Mycobacterial Infections
Completed NCT01879163 - Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults Phase 1
Completed NCT00146744 - Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults Phase 2
Completed NCT00291889 - Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults. Phase 1
Recruiting NCT04333485 - Tuberculosis (TB) Aftermath N/A
Completed NCT00730795 - Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults Phase 1
Completed NCT00600782 - Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region Phase 2
Withdrawn NCT04243031 - QuantiFERON Access Clinical Performance Study Protocol